Jazz Pharmaceuticals plc
NASDAQ:JAZZ
| Market Cap (Intraday) | 9.19B |
| Current PE | N/A |
| Forward PE | 8.71 |
| 2yr Forward PE | 8.46 |
| 10-Day MA | $149.02 |
| 50-Day MA | $157.49 |
| 200-Day MA | $141.07 |
Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ
Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 3200
Description
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.